Training in Pharmacology of Antineoplastic Agents

抗肿瘤药物药理学培训

基本信息

  • 批准号:
    7101017
  • 负责人:
  • 金额:
    $ 24.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-09-01 至 2010-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The Division of Medical Oncology, School of Pharmacy, and the Bone Marrow Transplant Program sponsor an interdisciplinary postdoctoral training program in the "Clinical Pharmacology of Antineoplastic Agents." The goal of this training program is to provide individuals with the complex skills necessary to develop antineoplastic agents, evaluate their properties, design clinical studies, and move these agents through the regulatory agencies into national trials. The preceptors involved in this training believe that there is an important need for scientists who are trained in the practical evaluation of chemotherapeutic agents to facilitate the movement of these agents from the laboratory bench to the bedside. The program includes 2-3 years of basic laboratory research training, required core courses, available lecture series and elective courses. An Executive Committee consisting of the directors of the three cooperating units will administer it, and a Mentor's Committee of three faculty members will monitor student progress. Trainees will be required to write a NIH style RO-1, give local research seminars, attend national meetings, and publish articles in peer-reviewed journals. The trainees will be evaluated on a yearly basis by the Program Director. The first four years of this training grant have been extremely successful. Of the eight trainees that have completed the program, three have joined academic medical centers and three have gone into cancer drug development in industry. Forty percent of the trainees have been women. One Hispanic male and almost equal numbers of M.D.s and Ph.D.s were trained. The training grant faculty taught two new core courses, one in cancer drug pharmacology and the other in cancer biology that became part of the Medical School curriculum. This unique training program provides an interactive environment in which M.D.s and Ph.Ds involved in all phases of antineoplastic agent development will train individuals in the preclinical and clinical science necessary to take anticancer agents from the bench to the bedside.
描述(由申请人提供):医学院肿瘤学部、药学院和骨髓移植项目资助“抗肿瘤药物临床药理学”的跨学科博士后培养计划。该培训计划的目标是为个人提供开发抗肿瘤药物所需的复杂技能,评估其特性,设计临床研究,并将这些药物通过监管机构进入国家试验。参与培训的教师认为,迫切需要受过化疗药物实际评估培训的科学家,以促进这些药物从实验室工作台到床边的移动。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

S. Gail Eckhardt其他文献

Population pharmacokinetic model of PI-88, a heparanase inhibitor
  • DOI:
    10.1007/s00280-009-1080-z
  • 发表时间:
    2009-07-25
  • 期刊:
  • 影响因子:
    2.300
  • 作者:
    Susan F. Hudachek;S. Gail Eckhardt;Barbara Hicks;Daniel L. Gustafson
  • 通讯作者:
    Daniel L. Gustafson
A Phase II Study of Irofulven (MGI 114) in Patients with Stage IV Melanoma
Irofulven (MGI 114) 在 IV 期黑色素瘤患者中的 II 期研究
  • DOI:
    10.1023/a:1016261918256
  • 发表时间:
    2002
  • 期刊:
  • 影响因子:
    3.4
  • 作者:
    A. Scott Pierson;P. Gibbs;J. Richards;P. Russ;S. Gail Eckhardt;R. Gonzalez
  • 通讯作者:
    R. Gonzalez
Sa1651: MICROBIAL IMMUNOMODULATION FOR ENHANCING IMMUNOTHERAPEUTIC EFFICACY IN A PATIENT-SPECIFIC COLORECTAL CANCER CHIP
  • DOI:
    10.1016/s0016-5085(22)61078-3
  • 发表时间:
    2022-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Yong Cheol Shin;Alexander Wu;Soyoun Min;Dae Sung Kim;Woojung Shin;Linda A. Feagins;S. Gail Eckhardt;R.Y. Declan Fleming;Hyun Jung Kim
  • 通讯作者:
    Hyun Jung Kim
Interrogating open issues in cancer precision medicine with patient-derived xenografts
用患者衍生的异种移植物来询问癌症精准医疗中的未解决问题
  • DOI:
    10.1038/nrc.2016.140
  • 发表时间:
    2017-01-20
  • 期刊:
  • 影响因子:
    66.800
  • 作者:
    Annette T. Byrne;Denis G. Alférez;Frédéric Amant;Daniela Annibali;Joaquín Arribas;Andrew V. Biankin;Alejandra Bruna;Eva Budinská;Carlos Caldas;David K. Chang;Robert B. Clarke;Hans Clevers;George Coukos;Virginie Dangles-Marie;S. Gail Eckhardt;Eva Gonzalez-Suarez;Els Hermans;Manuel Hidalgo;Monika A. Jarzabek;Steven de Jong;Jos Jonkers;Kristel Kemper;Luisa Lanfrancone;Gunhild Mari Mælandsmo;Elisabetta Marangoni;Jean-Christophe Marine;Enzo Medico;Jens Henrik Norum;Héctor G. Palmer;Daniel S. Peeper;Pier Giuseppe Pelicci;Alejandro Piris-Gimenez;Sergio Roman-Roman;Oscar M. Rueda;Joan Seoane;Violeta Serra;Laura Soucek;Dominique Vanhecke;Alberto Villanueva;Emilie Vinolo;Andrea Bertotti;Livio Trusolino
  • 通讯作者:
    Livio Trusolino

S. Gail Eckhardt的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('S. Gail Eckhardt', 18)}}的其他基金

Southwest Early Clinical Trials Consortium
西南早期临床试验联盟
  • 批准号:
    8725314
  • 财政年份:
    2014
  • 资助金额:
    $ 24.62万
  • 项目类别:
Southwest Early Clinical Trials Consortium
西南早期临床试验联盟
  • 批准号:
    9552381
  • 财政年份:
    2014
  • 资助金额:
    $ 24.62万
  • 项目类别:
Southwest Early Clinical Trials Consortium
西南早期临床试验联盟
  • 批准号:
    9552382
  • 财政年份:
    2014
  • 资助金额:
    $ 24.62万
  • 项目类别:
Southwest Early Clinical Trials Consortium
西南早期临床试验联盟
  • 批准号:
    9022449
  • 财政年份:
    2014
  • 资助金额:
    $ 24.62万
  • 项目类别:
DEVELOPMENTAL THERAPEUTICS
发育治疗
  • 批准号:
    7229215
  • 财政年份:
    2006
  • 资助金额:
    $ 24.62万
  • 项目类别:
Development of Mechanism-Based Anticancer Therapy
基于机制的抗癌疗法的发展
  • 批准号:
    7188524
  • 财政年份:
    2005
  • 资助金额:
    $ 24.62万
  • 项目类别:
Development of Mechanism-Based Anticancer Therapy
基于机制的抗癌疗法的发展
  • 批准号:
    7022288
  • 财政年份:
    2005
  • 资助金额:
    $ 24.62万
  • 项目类别:
Development of Mechanism-Based Anticancer Therapy
基于机制的抗癌疗法的发展
  • 批准号:
    7356374
  • 财政年份:
    2005
  • 资助金额:
    $ 24.62万
  • 项目类别:
Development of Mechanism-Based Anticancer Therapy
基于机制的抗癌疗法的发展
  • 批准号:
    7575675
  • 财政年份:
    2005
  • 资助金额:
    $ 24.62万
  • 项目类别:
Development of Mechanism-Based Anticancer Therapy
基于机制的抗癌疗法的发展
  • 批准号:
    6871591
  • 财政年份:
    2005
  • 资助金额:
    $ 24.62万
  • 项目类别:

相似海外基金

TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    2720213
  • 财政年份:
    1999
  • 资助金额:
    $ 24.62万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6513197
  • 财政年份:
    1999
  • 资助金额:
    $ 24.62万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    6894842
  • 财政年份:
    1999
  • 资助金额:
    $ 24.62万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    7648035
  • 财政年份:
    1999
  • 资助金额:
    $ 24.62万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    7462467
  • 财政年份:
    1999
  • 资助金额:
    $ 24.62万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6173875
  • 财政年份:
    1999
  • 资助金额:
    $ 24.62万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6376928
  • 财政年份:
    1999
  • 资助金额:
    $ 24.62万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6651598
  • 财政年份:
    1999
  • 资助金额:
    $ 24.62万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    7270561
  • 财政年份:
    1999
  • 资助金额:
    $ 24.62万
  • 项目类别:
BIOCHEMICAL PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物的生化药理学
  • 批准号:
    3163107
  • 财政年份:
    1978
  • 资助金额:
    $ 24.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了